[This corrects the article
✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
This is a correction notice, not new data — no actionable change; readers should consult the updated version of the original RCT for accurate figures before drawing clinical conclusions about MemoVigor 2 for tinnitus.
✦ Why It Matters ✦
Corrections to RCT data on tinnitus management matter because flawed figures can mislead clinical decision-making; audiologists relying on this trial should verify they are reading the corrected version.
✦ Key Points ✦
- 01This article is a published correction to an earlier RCT, not a new study.
- 02The original trial examined MemoVigor 2 (a nutraceutical supplement) versus placebo for recent-onset idiopathic tinnitus.
- 03Design was randomized, double-blind, and placebo-controlled — the highest-quality trial design.
- 04Nature and extent of the correction are not described in the available metadata.
- 05Clinicians should retrieve the corrected article before citing the original trial findings.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
MemoVigor 2 was evaluated in a randomized double-blind placebo-controlled trial for recent-onset idiopathic tinnitus.
studyunclear✦ Research metadata ✦
- PMID
- 42181866
- DOI
- 10.3389/fphar.2026.1856536.
- Journal
- Frontiers in Pharmacology
- Publication type
- editorial
- Evidence level
- 1b
- Population
- Adults with recent-onset idiopathic tinnitus
- Intervention
- MemoVigor 2 (nutraceutical supplement)
- Comparator
- Placebo
Primary outcomes
Effect of MemoVigor 2 on tinnitus severity or perception